J&J Commits $785 Million to Sail Biomedicines for In Vivo CAR-T — Before Any Clinical Proof

Johnson & Johnson agreed to pay $785 million in initial commitments, including a $465 million equity stake, to partner with Sail Biomedicines on in vivo CAR-T therapies. No in vivo CAR-T therapy has demonstrated durable clinical responses in peer-reviewed data. The deal bets on preclinical platform data before any clinical readout.